Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom
Sign Up to like & getrecommendations! Published in 2025 at "Epilepsia Open"
DOI: 10.1002/epi4.70021
Abstract: Investigate real‐world outcomes in drug‐resistant epilepsy (DRE) patients treated with cenobamate as adjunctive treatment to other antiseizure medications (ASMs) within the Early Access Programs (EAP) in Germany, France, and the United Kingdom. read more here.
Keywords: early access; real world; resistant epilepsy; access programs ... See more keywords
Getting to 90–90–90: Experiences from the MaxART Early Access to ART for All (EAAA) Trial in Eswatini
Sign Up to like & getrecommendations! Published in 2020 at "Current HIV/AIDS Reports"
DOI: 10.1007/s11904-020-00501-6
Abstract: Purpose of Review The MaxART Consortium—led by the Eswatini Ministry of Health—implemented multiple interventions between 2012 and 2017 to achieve UNAIDS 90–90–90 targets. We summarize key findings from community outreach strategies in support of the… read more here.
Keywords: eaaa trial; trial; hiv; early access ... See more keywords
Voting Rights and Immigrant Incorporation: Evidence from Norway
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Political Science"
DOI: 10.1017/s0007123417000643
Abstract: How do political rights influence immigrant integration? This study demonstrates that the timing of voting rights extension plays a key role in fostering political incorporation. In Norway, non-citizens are eligible to vote in local elections… read more here.
Keywords: early access; voting rights; immigrant incorporation; evidence ... See more keywords
OP173 Eligibility Criteria For “Accelerated Access” Approval: A Global Survey
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Technology Assessment in Health Care"
DOI: 10.1017/s0266462318001757
Abstract: Introduction: Several early access schemes (EAS) exist, which aim to accelerate patient access to new, potentially life-saving therapies. While some information exists on key schemes and their modalities, the determinants that drive adoption of a… read more here.
Keywords: eligibility criteria; early access; survey; percent ... See more keywords
PP81 Real World Data: The Early Access To Medicines Scheme Catches The Worm
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Technology Assessment in Health Care"
DOI: 10.1017/s0266462319002241
Abstract: Introduction The Early Access to Medicines Scheme (EAMS) aims to provide access to medicines prior to market authorization for patients with severe, life-threatening diseases who do not have adequate treatment options. An EAMS designation enables… read more here.
Keywords: access medicines; access; real world; early access ... See more keywords
Advancing early access policies for innovative cancer drugs: a scoping review and explorative analysis in the Italian setting
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Pharmaceutical Policy and Practice"
DOI: 10.1080/20523211.2024.2377697
Abstract: ABSTRACT Introduction Considering the clinical impact of innovative cancer therapies, policy makers strive to balance timely access and thorough value-assessment. While some European countries promoted early access schemes, Italy does not yet display a consolidated… read more here.
Keywords: early access; italian setting; analysis; access ... See more keywords
P723 Upadacitinib in Crohn’s disease: Real world experience from an early access program in Greece
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.0853
Abstract: Upadacitinib is a novel selective Janus kinase 1 inhibitor, recently approved for the management of Crohn’s disease (CD) by Food and Drug Administration. In Greece, upadacitinib is available through an early access program for refractory… read more here.
Keywords: disease; early access; access program; crohn disease ... See more keywords
Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaf034
Abstract: Abstract Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up… read more here.
Keywords: early access; access program; rezafungin; program ... See more keywords
Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: data from an early-access program in Italy.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of neurology"
DOI: 10.1111/ene.15325
Abstract: BACKGROUND Hereditary transthyretin amyloidosis (ATTRv) is a dominantly inherited, adult-onset, progressive and fatal disease caused by mutations in the transthyretin gene. Therapeutic agents approved for this disease include the TTR stabilizer tafamidis and the gene-silencing… read more here.
Keywords: early access; access program; program; hereditary transthyretin ... See more keywords
Real-world effectiveness and safety of amivantamab for exon 20 EGFR-mutant non-small cell lung cancer (NSCLC) in French early access program: Amexon 20 GFPC.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e20529
Abstract: e20529 Background: Amivantamab is a bispecific EGFR/MET antibody approved for patients with NSCLC with EGFR exon 20 insertions. In France, early access has made it possible to use it as a second or further-line treatment… read more here.
Keywords: early access; access program; real world; response ... See more keywords
Induction with upadacitinib in Crohn’s disease: real-world experience from an early-access program in Greece
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Gastroenterology"
DOI: 10.20524/aog.2025.0969
Abstract: Background Upadacitinib is a selective Janus kinase-1 inhibitor, approved for the management of Crohn’s disease (CD) by the United States Food & Drug Administration. In Greece, upadacitinib was initially available through an early-access program. Our… read more here.
Keywords: early access; greece; access program; crohn disease ... See more keywords